Welcome to our dedicated page for Akero Therapeutics SEC filings (Ticker: AKRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Akero Therapeutics, Inc. filings document material-event reporting for a clinical-stage biotechnology company developing efruxifermin for MASH and other serious metabolic diseases. The company’s Form 8-K disclosures include operating and financial results, material agreements, shareholder voting matters, governance matters and capital-structure information.
Recent filing subjects include the company’s Nasdaq-listed common stock, quarterly results reporting and the termination of a material loan agreement following repayment of obligations to Hercules Capital. These regulatory records also describe formal exhibit filings, financial-condition updates and agreement-related changes affecting Akero’s public-company obligations.
Jane Henderson, a director of Akero Therapeutics (AKRO), reported insider transactions dated 08/12/2025 showing linked non-derivative and derivative activity. The filing shows an acquisition of 3,000 common shares associated with a stock option having a conversion/exercise price of $7.009, and a sale of 3,000 common shares at $47.457. Following the reported transactions the filing shows she beneficially owned 9,398 shares of common stock directly. The disclosure also states that the related options are vested and currently exercisable.
Akero Therapeutics (AKRO) submitted a Form 144 reporting the proposed sale of 50,000 shares of common stock via J.P. Morgan Securities LLC on NASDAQ, with an aggregate market value reported as $2,414,000 and approximately 79,988,975 shares outstanding. The filing shows the shares were acquired by a stock option exercise and the acquisition date, payment date and approximate sale date are all listed as 08/12/2025, with payment in cash.
The form discloses no securities sold in the past three months and includes the seller’s representation about not possessing undisclosed material adverse information. Several issuer/filer identification fields in the provided content are blank, so the filing text here omits the named filer and named person for whose account the securities are to be sold.
Akero Therapeutics Form 144 filed for an insider sale of common stock. The notice reports an intended sale of 3,000 common shares with an aggregate market value of $142,371.90 from a total of 79,988,975 shares outstanding. The sale is listed for 08/12/2025 on NASDAQ through Morgan Stanley Smith Barney LLC.
The filing shows the securities were acquired and exercised on 08/12/2025 via a stock option exercise and paid in cash. It also states "Nothing to Report" for any securities sold during the past three months and includes the standard representation that the seller is not aware of any undisclosed material adverse information.
Schedule 13G/A disclosure: Wellington Management Group LLP and related Wellington entities report beneficial ownership of 3,409,946 shares of Akero Therapeutics common stock, representing 4.28% of the class. The filing shows shared voting power of 2,924,691 shares and shared dispositive power of 3,409,946, with no sole voting or dispositive power. The securities are owned of record by clients of Wellington’s investment advisers rather than by Wellington itself.
The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, consistent with a passive, institutional ownership disclosure under Schedule 13G/A.
Akero Therapeutics, Inc. filed a current report disclosing that it has announced its financial results for the quarter ended June 30, 2025. The company released these quarterly results through a press release dated August 8, 2025, which is included as Exhibit 99.1. This press release is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other SEC filings unless specifically referenced.
Akero Therapeutics (AKRO) Q2 2025 10-Q highlights: The clinical-stage biotech remains pre-revenue and focused on its FGF21 analog efruxifermin (EFX). Operating expenses rose 23% YoY to $80.9 m as Phase 3 SYNCHRONY trials (≈3,500 pts, three global studies) ramped, driving a quarterly net loss of $70.5 m (-$0.86/sh) versus $56.0 m (-$0.81/sh) a year ago. Six-month loss totalled $141.2 m, up 29%.
Balance sheet strengthened by a January 2025 follow-on offering (6.4 m shares & 2.0 m pre-funded warrants) and ATM sales, adding ~$389 m net. Cash, cash equivalents and marketable securities reached $1.09 b (vs $0.83 b YE-24), offsetting a $115.9 m operating cash burn YTD and covering the $35.7 m Hercules term loan (interest-only until Jan-26). Management projects ≥12 months liquidity.
Key takeaways for investors: 1) Ample capital should fund completion of Phase 3, but ongoing R&D spend (~$69 m/qtr) will keep losses high. 2) Share dilution lifted WAVG shares 18% YoY to 81.7 m; additional ATM capacity of $262 m remains. 3) Investment thesis hinges on EFX clinical success; no alternative revenue sources exist. 4) Standard biotech risks—trial delays, manufacturing, competition and regulatory—are detailed in Risk Factors.
Akero Therapeutics (AKRO) – Form 4 insider transaction
President & CEO Andrew Cheng reported two open-market sales on 10 July 2025 executed under a previously adopted Rule 10b5-1 trading plan dated 16 Aug 2024.
- 14,686 shares sold at a weighted-average price of $50.57.
- 15,314 shares sold at a weighted-average price of $51.732.
- Total shares sold: 30,000; estimated gross proceeds ≈ $1.53 million based on disclosed averages.
- Post-sale direct holdings: 520,757 common shares (down from 550,757), indicating the CEO retains roughly 94% of his prior stake.
No derivative securities were involved. The filing notes that detailed trade-by-trade pricing is available upon request.
While insider sales can signal caution, the modest size (about 5.5 % of Cheng’s holdings) and the existence of a pre-arranged plan reduce potential negative interpretation. There are no indications of material changes to Akero’s operations or outlook within this filing.